Created in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, London-based GSK (GlaxoSmithKline) ranks #10 with a brand value of USD $6.778 billion. GSK is made up of three world-leading businesses: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceutical business develops and makes medicines to treat a broad range of acute and chronic diseases and has leading global positions in respiratory disease and HIV with a portfolio of innovative and established medicines. The company focuses on respiratory illness and HIV, but also markets therapies that address cardiovascular, metabolic, and urological diseases.
GSK’s longevity, along with its diversity in the pharmaceutical sector, has engendered favorable perceptions of the brand among healthcare professionals (HCPs). The data illustrate that HCPs associate GSK with a breadth of expertise across multiple therapeutic areas and that GSK exhibits thought leadership in its field. GSK’s strength lies in harnessing its science and expertise to address both HCP and patient needs.
Over the past 12 months, GSK completed a three-part transaction with Novartis to consolidate its portfolio and hone its category expertise. GSK acquired Novartis’s global vaccines business (excluding influenza vaccines), sold its marketed oncology portfolio to Novartis, and partnered with Novartis on a new consumer healthcare venture.